chr3-37025734-A-G
Position:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP6_Very_Strong
The NM_000249.4(MLH1):c.1136A>G(p.Tyr379Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000403 in 1,613,162 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely benign (★★★).
Frequency
Genomes: 𝑓 0.000046 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000040 ( 0 hom. )
Consequence
MLH1
NM_000249.4 missense
NM_000249.4 missense
Scores
4
13
2
Clinical Significance
Conservation
PhyloP100: 4.43
Genes affected
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP6
Variant 3-37025734-A-G is Benign according to our data. Variant chr3-37025734-A-G is described in ClinVar as [Likely_benign]. Clinvar id is 142276.Status of the report is reviewed_by_expert_panel, 3 stars. Variant chr3-37025734-A-G is described in Lovd as [Likely_benign].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.1136A>G | p.Tyr379Cys | missense_variant | 12/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.1136A>G | p.Tyr379Cys | missense_variant | 12/19 | 1 | NM_000249.4 | ENSP00000231790.3 |
Frequencies
GnomAD3 genomes AF: 0.0000463 AC: 7AN: 151294Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
7
AN:
151294
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000477 AC: 12AN: 251454Hom.: 0 AF XY: 0.0000515 AC XY: 7AN XY: 135900
GnomAD3 exomes
AF:
AC:
12
AN:
251454
Hom.:
AF XY:
AC XY:
7
AN XY:
135900
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000397 AC: 58AN: 1461868Hom.: 0 Cov.: 34 AF XY: 0.0000440 AC XY: 32AN XY: 727236
GnomAD4 exome
AF:
AC:
58
AN:
1461868
Hom.:
Cov.:
34
AF XY:
AC XY:
32
AN XY:
727236
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000463 AC: 7AN: 151294Hom.: 0 Cov.: 31 AF XY: 0.0000136 AC XY: 1AN XY: 73792
GnomAD4 genome
AF:
AC:
7
AN:
151294
Hom.:
Cov.:
31
AF XY:
AC XY:
1
AN XY:
73792
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
2
ExAC
AF:
AC:
5
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Likely benign
Submissions summary: Uncertain:8Benign:5
Revision: reviewed by expert panel
LINK: link
Submissions by phenotype
not provided Uncertain:3Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Apr 17, 2024 | The MLH1 c.1136A>G (p.Tyr379Cys) variant has been reported in the published literature in individuals with breast cancer (PMIDs: 26898890 (2016), 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/)), ovarian cancer (PMID: 23047549 (2012)), suspected Lynch syndrome (PMIDs: 21404117 (2011), 14635101 (2003)), kidney cancer (PMID: 29684080 (2018)), and mesothelioma (PMID: 28687356 (2017)). This variant has also been observed in reportedly healthy individuals (PMID: 33471991 (2021)). Experimental studies indicate this variant has nearly no effect on MLH1 DNA repair activity (PMID: 32849802 (2020)). The frequency of this variant in the general population, 0.00014 (5/35438 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 02, 2019 | This variant is denoted MLH1 c.1136A>G at the cDNA level, p.Tyr379Cys (Y379C) at the protein level, and results in the change of a Tyrosine to a Cysteine (TAT>TGT). This variant has been observed in individuals with colorectal cancer, gastric cancer, ovarian cancer, renal cancer, breast cancer, sarcoma, and malignant pleural mesothelioma (Taylor 2003, Hardt 2011, Pal 2012, Ballinger 2016, Caminsky 2016, Betti 2017, Yehia 2018). MLH1 Tyr379Cys was observed at an allele frequency of 0.015% (5/34,416) in individuals of Latino ancestry in large population cohorts (Lek 2016). This variant is not located in a known functional domain. Protein-based in silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect. In addition, multiple splicing models predict that this variant may result in the creation of a cryptic splice donor site upstream of the natural splice donor site. However, in the absence of RNA or functional studies, the actual effect of this variant is unknown. Based on currently available evidence, it is unclear whether MLH1 Tyr379Cys is a pathogenic or benign variant. We consider it to be a variant of uncertain significance. - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jun 01, 2024 | MLH1: BS3:Supporting - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Apr 06, 2017 | Variant summary: The MLH1 c.1136A>G (p.Tyr379Cys) variant involves the alteration of a conserved nucleotide. 4/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). 5/5 splice prediction tools predict the variant to create a cryptic splice donor site. However, these predictions have yet to be confirmed by functional studies. This variant was found in 5/121182 control chromosomes at a frequency of 0.0000413, which does not exceed the estimated maximal expected allele frequency of a pathogenic MLH1 variant (0.0007105). The variant has been reported in patients with HNPCC, extra colonic cancer and epithelial ovarian cancer patients, however, without strong evidence for the causitive relationship between the variant and diseases. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as uncertain significance. Taken together, this variant is classified as VUS until additional evidence becomes available. - |
Hereditary cancer-predisposing syndrome Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Aug 07, 2021 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Dec 11, 2023 | This missense variant replaces tyrosine with cysteine at codon 379 of the MLH1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been performed for this variant. This variant has been reported in individuals affected with breast and/or ovarian cancer (PMID: 23047549, 26898890), colorectal cancer (PMID: 14635101, 21404117), melanoma (25148578), sarcoma (PMID: 27498913), and mesothelioma (PMID: 28687356). This variant has also been reported in individuals whose phenotypes suggest that this variant is not likely to be pathogenic (ClinVar SCV004018102.1). This variant has been identified in 15/282670 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 22, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Colorectal cancer, hereditary nonpolyposis, type 2 Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Mar 13, 2023 | This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Aug 29, 2016 | - - |
Lynch syndrome Uncertain:1Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jul 29, 2024 | This missense variant replaces tyrosine with cysteine at codon 379 of the MLH1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been performed for this variant. This variant has been reported in individuals affected with breast/ovarian cancer (PMID: 26898890), ovarian cancer (PMID: 23047549), colorectal cancer (PMID: 14635101, 21404117), melanoma (25148578), sarcoma (PMID: 27498913), and mesothelioma (PMID: 28687356). This variant has also been reported in individuals whose phenotypes suggest that this variant is not likely to be pathogenic (ClinVar variation ID: 142276). This variant has been identified in 15/282670 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Likely benign, reviewed by expert panel | curation | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Dec 19, 2018 | Multifactorial likelihood analysis posterior probability < 0.05 (0.005) - |
MLH1-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 13, 2023 | The MLH1 c.1136A>G variant is predicted to result in the amino acid substitution p.Tyr379Cys. This variant has been reported in individuals with colorectal and ovarian cancer, and an asbestos-exposed patient with malignant pleural mesothelioma; although no evidence was provided to determine its pathogenicity (Taylor et al. 2003. PubMed ID: 14635101; Pal et al. 2012. PubMed ID: 23047549; Betti ett al. 2017. PubMed ID: 28687356). This variant is reported in 0.014% of alleles in individuals of Latino descent in gnomAD and is interpreted as likely benign in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/142276/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Hereditary nonpolyposis colorectal neoplasms Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Uncertain
D
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Pathogenic
D;.;.;.;.;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;.;.;.;D
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D;D;D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Uncertain
M;.;.;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D;D;D;D
REVEL
Pathogenic
Sift
Uncertain
D;D;D;D;D;D
Sift4G
Uncertain
D;D;D;D;D;D
Polyphen
D;.;.;.;.;.
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at